.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,800,807

« Back to Dashboard
Patent 5,800,807 protects LOTEMAX and is included in one NDA.

This patent has ten patent family members in nine countries.

Summary for Patent: 5,800,807

Title: Ophthalmic compositions including glycerin and propylene glycol
Abstract:There are disclosed ophthalmic compositions having high water-binding properties which are useful as: moisturizing and lubricating (i.e. artificial tear) solutions, dry eye therapies, contact lens wetting and lubricating solutions, and as delivery vehicles for ophthalmic drugs. The subject compositions include glycerin in combination with propylene glycol. The subject compositions may further include cellulose derivatives, e.g. hydroxypropyl methyl cellulose, along with preservatives, e.g. benzylalkonium chloride, PHMB, sorbic acid, etc. Preferred compositions have at least 11% bound water, a pH from about 7.1 to 7.5, and an osmolality between about 280 to about 320 mOsm/Kg.
Inventor(s): Hu; Zhenze (Pittsford, NY), Denick; John (Pittsford, NY)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:08/794,690
Patent Claim Types:
see list of patent claims
Composition; Formulation; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Not categorized
Back Citations: 29th percentile
Forward Citations: 20th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872-001Sep 28, 2012RXYes5,800,807► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,800,807

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia6253398► subscribe
Australia723024► subscribe
Brazil9807117► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc